PDF herunterladen
Synfacts 2008(10): 1012-1012  
DOI: 10.1055/s-2008-1078181
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag Stuttgart ˙ New York

Synthesis of JNJ-26076713

Contributor(s): Philip Kocienski, Stewart Eccles
W. A. Kinney et al.*
Johnson & Johnson Pharmaceutical Research and Development, Spring House, USA
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
22. September 2008 (online)

    Lizenzen und Reprints

Significance

JNJ-26076713 is an αVβ3/αVβ5 integrin antagonist with efficacy in eye disease models of angiogenesis and vascular permeability. JNJ-26076713 shows good potency, oral bioavailability, selectivity and half-life.